(function(){var loadHandler=window['sl_{B169E353-1691-4AFC-B51D-F07AF60FC333}'];loadHandler&&loadHandler(25, '<div id="spr0_58788388"><div id="spr1_58788388" class="kern slide"><img id="img3_58788388" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_58788388" class="kern slide"><img id="img0_58788388" src="data/img3.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_58788388" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_58788388" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_58788388" src="data/img8.png" width="721.48" height="43.101" alt="" style="top:497.416px;"/><div id="spr3_58788388" style="left:657.715px;top:499.855px;"><img id="img2_58788388" src="data/img9.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_58788388" style="left:-1.875px;top:25.631px;"><div style="width:0px;"><span id="txt0_58788388" data-width="606.933594" style="left:56.812px;top:5.458px;">PCSK9 Inhibitors and Their Indications</span></div></div><div id="spr5_58788388" style="left:18.061px;top:502.353px;"><div style="width:0px;"><span id="txt1_58788388" class="nokern" data-width="589.775391" style="left:7.2px;top:-3.108px;">ASCVD, atherosclerotic cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; HoFH, homozygous familial hypercholesterolemia; LDL-C, low</span></div><div style="width:0px;"><span id="txt2_58788388" class="nokern" data-width="398.867188" style="left:7.2px;top:8.892px;">density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin kexin type 9.; MI, myocardial infarction</span></div><div style="width:0px;"><span id="txt3_58788388" class="nokern relpos" data-width="9.121094" style="left:7.2px;top:20.892px;">1. </span><span id="txt4_58788388" class="nokern relpos" data-width="207.615234" style="left:7.195px;top:21.814px;">Alirocumab Canadian Product Monograph, August 13, 2019; 2. </span><span id="txt5_58788388" class="nokern relpos" data-width="192.027832" style="left:7.19px;top:21.814px;">Evolocumab Canadian Product Monograph, June 11, 2019</span></div></div><div id="spr6_58788388" style="left:6.729px;top:105.105px;"><div style="width:0px;"><span id="txt6_58788388" class="relpos" data-width="63.150391" style="left:7.2px;top:4.403px;">Alirocumab</span><span id="txt7_58788388" class="relpos" style="left:7.195px;top:4.556px;">1</span></div><div style="width:0px;"><span id="txt8_58788388" class="nokern relpos" style="left:7.2px;top:22.897px;">―</span><span id="txt9_58788388" class="relpos" data-width="171.714844" style="left:19.862px;top:22.769px;">Prevention of Cardiovascular Events</span></div><div style="width:0px;"><span id="txt10_58788388" class="nokern relpos" style="left:43.2px;top:38.74px;">•</span><span id="txt11_58788388" class="relpos" data-width="263.671875" style="left:56.999px;top:38.737px;">indicated in combination with a maximum tolerated dose of a</span></div><div style="width:0px;"><span id="txt12_58788388" data-width="282.814453" style="left:61.2px;top:54.577px;">statin, with or without other lipid lowering therapies, to reduce the</span></div><div style="width:0px;"><span id="txt13_58788388" data-width="254.355469" style="left:61.2px;top:70.417px;">risk of myocardial infarction, ischemic stroke, and unstable</span></div><div style="width:0px;"><span id="txt14_58788388" data-width="247.822266" style="left:61.2px;top:86.257px;">angina requiring hospitalization in adults with established</span></div><div style="width:0px;"><span id="txt15_58788388" data-width="102.837891" style="left:61.2px;top:102.097px;">cardiovascular disease.</span></div><div style="width:0px;"><span id="txt16_58788388" class="nokern relpos" style="left:7.2px;top:117.938px;">―</span><span id="txt17_58788388" class="relpos" data-width="109.927734" style="left:19.862px;top:117.809px;">Primary Hyperlipidemia</span></div><div style="width:0px;"><span id="txt18_58788388" class="nokern relpos" style="left:43.2px;top:133.78px;">•</span><span id="txt19_58788388" class="relpos" data-width="263.671875" style="left:56.999px;top:133.777px;">indicated in combination with a maximum tolerated dose of a</span></div><div style="width:0px;"><span id="txt20_58788388" data-width="282.814453" style="left:61.2px;top:149.617px;">statin, with or without other lipid lowering therapies, to reduce the</span></div><div style="width:0px;"><span id="txt21_58788388" data-width="254.355469" style="left:61.2px;top:165.457px;">risk of myocardial infarction, ischemic stroke, and unstable</span></div><div style="width:0px;"><span id="txt22_58788388" data-width="247.822266" style="left:61.2px;top:181.297px;">angina requiring hospitalization in adults with established</span></div><div style="width:0px;"><span id="txt23_58788388" data-width="102.837891" style="left:61.2px;top:197.137px;">cardiovascular disease.</span></div><div style="width:0px;"><span id="txt24_58788388" class="nokern relpos" style="left:43.2px;top:212.98px;">•</span><span id="txt25_58788388" class="relpos" data-width="274.617188" style="left:56.999px;top:212.978px;">indicated for the reduction of low-density lipoprotein cholesterol</span></div><div style="width:0px;"><span id="txt26_58788388" data-width="261.416016" style="left:61.2px;top:228.818px;">(LDL-C) in adults with primary hyperlipidemia (heterozygous</span></div><div style="width:0px;"><span id="txt27_58788388" data-width="108.837891" style="left:61.2px;top:244.657px;">familial and non-familial):</span></div><div style="width:0px;"><span id="txt28_58788388" class="nokern relpos" style="left:79.2px;top:260.5px;">•</span><span id="txt29_58788388" class="relpos" data-width="238.529297" style="left:92.999px;top:260.497px;">As an adjunct to diet and statin therapy, with or without</span></div><div style="width:0px;"><span id="txt30_58788388" data-width="128.537109" style="left:97.2px;top:276.337px;">other lipid-lowering therapies;</span></div><div style="width:0px;"><span id="txt31_58788388" class="nokern relpos" style="left:79.2px;top:292.18px;">•</span><span id="txt32_58788388" class="relpos" data-width="242.906250" style="left:92.999px;top:292.177px;">As an adjunct to diet, as monotherapy or in combination</span></div><div style="width:0px;"><span id="txt33_58788388" data-width="247.265625" style="left:97.2px;top:308.017px;">with other non-statin lipid modifying therapies, in patients</span></div><div style="width:0px;"><span id="txt34_58788388" data-width="154.259766" style="left:97.2px;top:323.857px;">for whom a statin is contraindicated</span></div></div><div id="spr7_58788388" style="top:-3.205px;"><div style="width:0px;"><span id="txt35_58788388" class="nokern" style="left:7.2px;top:4.363px;">.</span></div></div><div id="spr8_58788388" style="left:366.974px;top:104.41px;"><div style="width:0px;"><span id="txt36_58788388" class="relpos" data-width="68.263672" style="left:7.2px;top:4.403px;">Evolocumab</span><span id="txt37_58788388" class="relpos" style="left:7.195px;top:4.556px;">2</span></div><div style="width:0px;"><span id="txt38_58788388" class="nokern relpos" style="left:7.2px;top:22.898px;">―</span><span id="txt39_58788388" class="relpos" data-width="171.714844" style="left:19.862px;top:22.769px;">Prevention of Cardiovascular Events</span></div><div style="width:0px;"><span id="txt40_58788388" class="nokern relpos" style="left:43.2px;top:38.74px;">•</span><span id="txt41_58788388" class="relpos" data-width="283.382813" style="left:56.999px;top:38.737px;">Adjunct to diet and standard of care therapy (including moderate-</span></div><div style="width:0px;"><span id="txt42_58788388" data-width="280.640625" style="left:61.2px;top:54.577px;">to high-intensity statin therapy alone or in combination with other</span></div><div style="width:0px;"><span id="txt43_58788388" data-width="283.880859" style="left:61.2px;top:70.418px;">lipid-lowering therapy), to reduce the risk of myocardial infarction,</span></div><div style="width:0px;"><span id="txt44_58788388" data-width="258.199219" style="left:61.2px;top:86.257px;">stroke, and coronary revascularization in adult patients with</span></div><div style="width:0px;"><span id="txt45_58788388" data-width="169.570313" style="left:61.2px;top:102.097px;">atherosclerotic cardiovascular disease.</span></div><div style="width:0px;"><span id="txt46_58788388" class="nokern relpos" style="left:7.2px;top:117.937px;">―</span><span id="txt47_58788388" class="relpos" data-width="266.865234" style="left:19.862px;top:117.809px;">Primary Hyperlipidemia (including Heterozygous Familial</span></div><div style="width:0px;"><span id="txt48_58788388" data-width="106.089844" style="left:29.7px;top:133.649px;">Hypercholesterolemia)</span></div><div style="width:0px;"><span id="txt49_58788388" class="nokern relpos" style="left:43.2px;top:149.62px;">•</span><span id="txt50_58788388" class="relpos" data-width="264.234375" style="left:56.999px;top:149.618px;">indicated for the reduction of elevated low-density lipoprotein</span></div><div style="width:0px;"><span id="txt51_58788388" data-width="278.929688" style="left:61.2px;top:165.458px;">cholesterol (LDL-C) in adult patients with primary hyperlipidemia</span></div><div style="width:0px;"><span id="txt52_58788388" data-width="239.578125" style="left:61.2px;top:181.298px;">(including heterozygous familial hypercholesterolemia):</span></div><div style="width:0px;"><span id="txt53_58788388" class="nokern relpos" style="left:79.2px;top:197.14px;">•</span><span id="txt54_58788388" class="relpos" data-width="237.439453" style="left:92.999px;top:197.138px;">as an adjunct to diet and statin therapy, with or without</span></div><div style="width:0px;"><span id="txt55_58788388" data-width="230.285156" style="left:97.2px;top:212.978px;">other lipid-lowering therapies, in patients who require</span></div><div style="width:0px;"><span id="txt56_58788388" data-width="123.609375" style="left:97.2px;top:228.818px;">additional lowering of LDL-C</span></div><div style="width:0px;"><span id="txt57_58788388" class="nokern relpos" style="left:79.2px;top:244.66px;">•</span><span id="txt58_58788388" class="relpos" data-width="237.984375" style="left:92.999px;top:244.657px;">as an adjunct to diet, alone or in combination with non-</span></div><div style="width:0px;"><span id="txt59_58788388" data-width="228.644531" style="left:97.2px;top:260.497px;">statin lipid-lowering therapies, in patients for whom a</span></div><div style="width:0px;"><span id="txt60_58788388" data-width="102.849609" style="left:97.2px;top:276.337px;">statin is contraindicated</span></div><div style="width:0px;"><span id="txt61_58788388" class="nokern relpos" style="left:7.2px;top:292.178px;">―</span><span id="txt62_58788388" class="relpos" data-width="206.712891" style="left:19.862px;top:292.049px;">Homozygous Familial Hypercholesterolemia</span></div><div style="width:0px;"><span id="txt63_58788388" class="nokern relpos" style="left:43.2px;top:308.02px;">•</span><span id="txt64_58788388" class="relpos" data-width="268.605469" style="left:56.999px;top:308.018px;">adjunct to diet and other LDL-lowering therapies (e.g., statins,</span></div><div style="width:0px;"><span id="txt65_58788388" data-width="255.486328" style="left:61.2px;top:323.858px;">ezetimibe, LDL apheresis) in adult patients and adolescent</span></div><div style="width:0px;"><span id="txt66_58788388" data-width="252.738281" style="left:61.2px;top:339.698px;">patients aged 12 years and over with homozygous familial</span></div><div style="width:0px;"><span id="txt67_58788388" data-width="278.085938" style="left:61.2px;top:355.538px;">hypercholesterolemia (HoFH) who require additional lowering of</span></div><div style="width:0px;"><span id="txt68_58788388" data-width="31.160156" style="left:61.2px;top:371.378px;">LDL-C.</span></div></div></div></div>');})();